What to Do When UnitedHealthcare Denies Zepbound: Step-by-Step Appeal

Introduction

UnitedHealthcare processes pharmacy benefits through OptumRx, so Zepbound® denials come back as OptumRx adverse determinations. The level-1 appeal goes to OptumRx, not directly to UnitedHealthcare.

Denial reasons cluster around six issues: prior authorization criteria not met, step therapy (often Wegovy® or an older agent first), BMI below threshold, weight-loss drug carve-out by the employer, OSA criteria missing for the sleep apnea indication, and incomplete documentation of a structured weight management program. Each has a specific counter on appeal.

CMS data from 2023 puts the overturn rate at roughly 41 percent for commercial denials when patients file a level-1 internal appeal with new clinical documentation. Zepbound appeals gained an extra lever in 2026 because the FDA approved Zepbound for moderate-to-severe obstructive sleep apnea in December 2024 based on SURMOUNT-OSA. That OSA indication is a separate pathway with relaxed criteria on most UHC plans.

At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.

Why Does UnitedHealthcare Deny Zepbound?

Six denial codes account for roughly 90 percent of UHC Zepbound rejections. The codes are PA-NOT-MET, NF (non-formulary), STEP-REQ (step therapy required, often Wegovy first), BMI-NOT-MET, EMP-EXCL (employer carve-out), and OSA-DOCS-MISSING (under the OSA indication).

Quick Answer: UnitedHealthcare processes Zepbound through OptumRx; level-1 appeals go to OptumRx first

Pull your OptumRx adverse determination letter and find the reason code. The wording sits near a phrase reading “reason for adverse determination.” The appeal strategy depends on which code applies.

A step therapy requirement for Wegovy first creates a paradox if your plan also denied Wegovy. The workaround is a medical necessity exception citing prescriber preference based on SURMOUNT-1 (Jastreboff et al. 2022, NEJM) showing 20.9 percent weight loss at 72 weeks with tirzepatide, versus 14.9 percent with semaglutide in STEP 1 (Wilding et al. 2021, NEJM).

What Is UnitedHealthcare’s 2026 Prior Authorization for Zepbound?

UHC’s 2026 commercial PA for Zepbound requires five things: BMI of 30 or higher, or BMI 27 to 29.9 with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, OSA, CVD), documentation of a structured weight management program for at least 6 months in the past 24 months, prescriber attestation that lifestyle changes alone have been inadequate, age 18 or older, and concurrent reduced-calorie diet and physical activity.

Some UHC plans add a step therapy requirement for Wegovy or an older weight-loss agent first. The step requirement can be waived with documented contraindication, intolerance, or insufficient response.

For the OSA indication after SURMOUNT-OSA, UHC’s PA requires confirmed AHI of 15 or higher on polysomnography and BMI of 30 or higher. The 6-month lifestyle program requirement is typically waived under the OSA pathway.

How Do I File a Level-1 Internal Appeal for Zepbound?

You have 180 days from the denial date to file a level-1 internal appeal. The submission goes to OptumRx at the address on the denial letter, typically a PO Box in Schaumburg, Illinois or Irvine, California.

The appeal packet should include a signed appeal letter from you, a Letter of Medical Necessity signed by your prescriber, chart notes from the past 12 months, BMI and weight history, documentation of the 6-month weight management program, and prior medication trials with dates and outcomes. If you’re applying under the OSA indication, include the polysomnography report with AHI data.

OptumRx has 30 days to respond on a standard appeal and 72 hours on an expedited appeal. Expedited appeals require prescriber attestation that delay would seriously jeopardize health. Reasonable triggers include uncontrolled type 2 diabetes, established CVD, or severe OSA with daytime symptoms.

What Should the Letter of Medical Necessity Say?

The LMN is the single most important document. It should be on prescriber letterhead, signed and dated, and limited to two pages. OptumRx reviewers spend about 6 minutes per file on average.

Hit five points. First, current BMI and weight, plus BMI trend over 24 months. Second, every comorbidity that meets UHC criteria with ICD-10 codes. Third, prior weight-loss interventions with dates and outcomes, including any prior GLP-1 trials, phentermine, Contrave, Qsymia, or commercial programs. Fourth, clinical rationale citing SURMOUNT-1 (Jastreboff et al. 2022, NEJM) showing 20.9 percent weight loss at 72 weeks, SURMOUNT-2 (Garvey et al. 2023, Lancet) for patients with type 2 diabetes, and SURMOUNT-OSA for the sleep apnea indication if applicable. Fifth, a statement that lifestyle modifications alone have not produced sustained clinical response.

A focused two-page LMN beats a five-page one almost every time.

What Clinical Evidence Does UnitedHealthcare Respect?

OptumRx and UHC’s P&T committee reference specific trials when updating coverage policy. Citing those trials by name puts your appeal in their internal language.

For Zepbound in 2026, the strongest references are SURMOUNT-1 (Jastreboff et al. 2022, NEJM) showing 20.9 percent weight loss at 72 weeks, SURMOUNT-2 (Garvey et al. 2023, Lancet) showing 15.7 percent weight loss in patients with type 2 diabetes, SURMOUNT-3 (Wadden et al. 2023, Nature Medicine) for the intensive behavioral therapy combination, SURMOUNT-4 for weight maintenance after initial treatment, and SURMOUNT-OSA for the sleep apnea indication.

Pick the two trials most relevant to your clinical situation. A focused appeal looks more credible than a literature dump.

Key Takeaway: 2026 UHC PA requires BMI of 30 or higher, or 27 with comorbidity, plus a 6-month documented weight management program

What If the First Appeal Is Denied?

You can file a level-2 internal appeal within 60 days of the level-1 denial, and pursue external review through your state commissioner in parallel.

The level-2 internal appeal at UnitedHealthcare goes to a different reviewer, usually a board-certified physician. The packet can include the same documents plus a peer-to-peer review request, where your prescriber speaks directly with UHC’s medical director. Peer-to-peer reviews are typically granted and significantly improve overturn rates.

External review through your state insurance commissioner is independent and decisions are binding. The deadline is usually 4 months from the final internal denial. The IRO assigns a board-certified physician in endocrinology, obesity medicine, or pulmonology (for OSA cases). The review costs nothing. Approval rates at external review run around 50 percent for prescription drug denials.

How Does the OSA Indication Change the Appeal?

If you have moderate-to-severe obstructive sleep apnea with documented AHI of 15 or higher on polysomnography, the OSA indication is a separate appeal pathway with different criteria.

The FDA approved Zepbound for OSA in December 2024 after SURMOUNT-OSA showed significant AHI reduction in patients with moderate-to-severe OSA and obesity. The trial reduced AHI by about 27 events per hour in the treatment arm versus about 4 in placebo, and 43 percent of treatment-arm patients reached AHI of 5 or fewer events per hour.

The LMN should explicitly say “requested for moderate-to-severe OSA per FDA-approved indication based on SURMOUNT-OSA.” Cite the polysomnography results. Most UHC plans waive the 6-month lifestyle program requirement under the OSA pathway.

What If My UnitedHealthcare Plan Carves Out Weight-loss Drugs?

This is the hardest denial to overturn because the benefit comes from the employer, not UHC’s medical policy. You have three practical options.

First, ask HR whether the carve-out applies to all indications or only the obesity indication. The OSA indication may be covered separately on self-funded plans because it is a respiratory disease benefit, not a weight-loss benefit. Second, request a formulary exception based on medical necessity with documented OSA, type 2 diabetes, or CVD. Third, consider cash-pay options. The Eli Lilly LillyDirect cash pharmacy offers Zepbound single-dose vials at $349 to $499 per month, available to commercially-insured patients without coverage and to cash-pay patients.

Compounded tirzepatide is no longer available through 503A pharmacies after the FDA resolved the tirzepatide shortage in late 2024. Compounded semaglutide remains a legal option through licensed telehealth providers like TrimRx, with a free assessment quiz determining eligibility.

How Long Does the Full Appeal Process Take?

A standard level-1 internal appeal takes 30 days. A level-2 takes another 30 days. External review is usually 45 days but can be expedited to 72 hours with documented urgent medical need.

Full timeline through every level: roughly 4 to 5 months from initial denial to a final external review decision. Expedited appeals can compress this to 10 to 14 days.

While appeals are pending, options include paying cash with a plan for retroactive reimbursement if the appeal succeeds, using LillyDirect vials at the cash-pay rate, or starting a personalized treatment plan with compounded semaglutide through a telehealth provider during the review.

Bottom line: You have 180 days to file a level-1 internal appeal and 4 months for external review

FAQ

Can I Appeal a UHC Zepbound Denial Without My Doctor’s Help?

Possible but rare to succeed. The Letter of Medical Necessity from the prescriber carries clinical authority that a patient-written letter cannot match. Most prescribers will write an LMN if you provide the denial letter and ask in writing.

Does UnitedHealthcare Cover Zepbound for Medicare Patients?

No, in most cases. Medicare Part D does not cover Zepbound for obesity as of 2026. CMS has not extended Part D coverage to the obesity indication for tirzepatide. Some UHC Medicare Advantage plans cover Zepbound for the OSA indication after the December 2024 approval, but this varies by plan.

Does UnitedHealthcare Require Wegovy STEP Therapy Before Zepbound?

Some UHC plans require prior trial of Wegovy or another GLP-1 first. The step requirement can be waived with documented contraindication, intolerance, or insufficient response. A documented prior failure on Wegovy due to GI tolerability or insufficient weight loss after a full titration trial is the easiest waiver.

How Much Does Zepbound Cost with UHC Coverage?

With PA approved on Tier 3, expect a copay of $40 to $100 per month for commercial plans. High-deductible plans charge the full negotiated rate (around $900 to $1,000 per month) until the deductible is met. Without coverage, brand Zepbound lists at about $1,059 per month, with the LillyDirect direct-cash program running $349 to $499 per month for vials.

Can I Get an Expedited Appeal If I Have Severe OSA?

Yes. Severe OSA with documented AHI of 30 or higher, documented daytime sleepiness, or evidence of cardiovascular complications support an expedited appeal request. The prescriber must attest in writing that delay would jeopardize health.

What Documents Does OptumRx Want in a Zepbound Appeal?

A signed appeal letter from you, a Letter of Medical Necessity from your prescriber, chart notes from the past 12 months, BMI and weight history, documentation of the 6-month weight management program, prior medication trials with dates, and (for the OSA pathway) a polysomnography report with AHI documentation.

Is There a Zepbound Savings Program Through Eli Lilly?

Yes. The Lilly Savings Card can bring eligible commercially-insured patients to as low as $25 per month for Zepbound pens for short periods. The LillyDirect direct-cash pharmacy offers Zepbound single-dose vials at $349 to $499 per month for cash-pay patients, available without insurance approval through a connected telehealth assessment.

Disclaimer: This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.